HC Wainwright Comments on Curis’ Q3 Earnings (NASDAQ:CRIS)

Curis, Inc. (NASDAQ:CRIS) – Stock analysts at HC Wainwright raised their Q3 2026 EPS estimates for shares of Curis in a research report issued on Monday, August 17th. HC Wainwright analyst S. Nik now expects that the biotechnology company will post earnings per share of ($2.29) for the quarter, up from their previous estimate of ($5.87). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Curis’ current full-year earnings is ($33.29) per share. HC Wainwright also issued estimates for Curis’ Q4 2026 earnings at ($1.50) EPS, FY2026 earnings at ($15.65) EPS and FY2027 earnings at ($57.10) EPS.

Several other research firms have also recently weighed in on CRIS. Wall Street Zen cut Curis to a “strong sell” rating in a research report on Saturday, August 8th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Curis in a research report on Friday, July 17th. Finally, Zacks Research cut Curis from a “hold” rating to a “strong sell” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Reduce” and a consensus target price of $43.00.

Curis Trading Down 5.6%

Shares of CRIS opened at $1.70 on Wednesday. The stock has a 50 day moving average of $5.54 and a 200 day moving average of $11.45. The company has a market capitalization of $3.55 million, a price-to-earnings ratio of -0.12 and a beta of 3.13. Curis has a 12 month low of $1.54 and a 12 month high of $39.00.

Curis (NASDAQ:CRIS) last posted its earnings results on Friday, August 14th. The biotechnology company reported ($4.02) EPS for the quarter, topping the consensus estimate of ($6.95) by $2.93. Curis had a negative net margin of 80.29% and a negative return on equity of 4,169.81%.

Hedge Funds Weigh In On Curis

Several institutional investors and hedge funds have recently bought and sold shares of the company. Squarepoint Ops LLC lifted its stake in shares of Curis by 17.9% during the 3rd quarter. Squarepoint Ops LLC now owns 59,140 shares of the biotechnology company’s stock valued at $98,000 after buying an additional 8,973 shares in the last quarter. Jane Street Group LLC grew its stake in Curis by 71.8% in the 4th quarter. Jane Street Group LLC now owns 25,323 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 10,586 shares in the last quarter. XTX Topco Ltd purchased a new position in Curis in the 4th quarter valued at approximately $26,000. Maverick Capital Ltd. boosted its position in shares of Curis by 7.8% in the second quarter. Maverick Capital Ltd. now owns 681,381 shares of the biotechnology company’s stock valued at $1,472,000 after acquiring an additional 49,554 shares during the period. Finally, Focused Wealth Management Inc grew its stake in Curis by 83.4% during the first quarter. Focused Wealth Management Inc now owns 109,746 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 49,900 shares in the last quarter. 29.97% of the stock is owned by institutional investors.

Curis Company Profile

Curis, Inc is a biotechnology company focused on the discovery, development and commercialization of targeted small molecule and antibody therapeutics for the treatment of cancer. The company’s research centers on exploiting key signaling pathways and tumor microenvironment interactions to develop compounds with the potential to address unmet medical needs. Curis’ proprietary pipeline includes multiple programs at various stages of clinical and preclinical development, reflecting its emphasis on innovative oncology drug candidates.

Among Curis’ lead assets is CA-4948, an oral inhibitor of interleukin-1 receptor–associated kinase 4 (IRAK4) partnered with Ikena Oncology, which is being evaluated in hematologic malignancies and solid tumors.